Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
19/09/2024 13:53
Sept 19 (Reuters) - Kiromic Biopharma Inc KRBP.PK :
* KIROMIC BIOPHARMA: ADVANCES DELTACEL-01 INTO EXPANSION
PHASE
FOLLOWING SAFETY MONITORING COMMITTEE'S UNANIMOUS RECOMMENDATION
Source text for Eikon: ID:nBwb8X81Ma
Further company coverage: KRBP.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site